Please provide your email address to receive an email when new articles are posted on . BARCELONA — Medium to long-term survival and other outcomes of liver transplant recipients with hepatitis C ...
MAVIRET is the first and only oral eight-week pan-genotypic treatment option approved for people with acute or chronic ...
The combination of daclatasvir, a hepatitis C virus (HCV) NS5A inhibitor, and the NS5B inhibitor sofosbuvir has shown efficacy in patients with HCV monoinfection. Data are lacking on the efficacy and ...
Advances in treatment for hepatitis C virus (HCV) have the potential to generate considerable spillover benefits to patients awaiting transplants, especially among those with non—HCV-mediated liver ...
Empowering women, eliminating viral hepatitis: Gilead’s vision to help drive public health solutions
The fight against viral hepatitis has witnessed both remarkable triumphs and persistent challenges. As a doctor and researcher, I have witnessed firsthand how groundbreaking advancements in treatment ...
New guidelines from the Centers for Disease Control and Prevention (CDC) outline a "test and treat" strategy for healthcare personnel (HCP) with potential occupational exposure to hepatitis C virus ...
Please provide your email address to receive an email when new articles are posted on . HCV testing provides valuable information that aids in disease prevention and in the initiation of care.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback